MBA Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

MBA Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,268	Closed	-$201	–	137
2021 Q1	$201	Buy	+2,268	New	+$225K	0.11%	130

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SDH

Sloy Dahl & Holst Vancouver, Washington $728M AUM 37.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MBA Advisors's ARKG Position: Q2 2021 in Review

MBA Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2021, closing a stake of 2,268 shares — an estimated $201 sold.

MBA Advisors first reported a position in ARKG in Q1 2021 and held it in 1 quarter. The position peaked at $201 in Q1 2021. 512 funds tracked by Wall St. Rank hold ARKG as of Q2 2021.

MBA Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2021 after selling out during the quarter.
MBA Advisors sold 2,268 ARK Genomic Revolution ETF shares in Q2 2021, an estimated $201.
MBA Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 1 quarter.
MBA Advisors's ARK Genomic Revolution ETF position peaked at $201 in Q1 2021.
512 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2021.

Based on MBA Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.